SCHEMBL2134783

SCHEMBL2134783

COc1ccc(N)c(N)c1-c1nc(Cl)ncc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ ADORA2A P29274 2/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ HSP90AA1 P07900 4/20 0.35
▸ HSP90AB1 P08238 2/20 0.35
▸ MAPT P10636 2/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ FGB P02675 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20162223 0.78 RPS6KA5 (0.35) ALDH1A1SMN1; SMN2KDM4EMAPTRPS6KA5
SCHEMBL4824253 0.74 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2KDM4EHSP90AA1HSP90AB1
SCHEMBL30936977 0.69 RPS6KA5 (0.36) ALDH1A1SMN1; SMN2KDM4EMAPTMAPK1
SCHEMBL3334777 0.68 RPS6KA5 (0.44) ALDH1A1SMN1; SMN2KDM4EADORA2AADORA1
SCHEMBL10486228 0.66 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2KDM4EADORA2AMAPT
SCHEMBL30919916 0.66 ADORA1 (0.50) ALDH1A1SMN1; SMN2KDM4EADORA2AADORA1
SCHEMBL30919634 0.66 ADORA1 (0.50) ALDH1A1SMN1; SMN2KDM4EADORA2AADORA1
SCHEMBL27264298 0.66 ADORA1 (0.50) ALDH1A1SMN1; SMN2KDM4EADORA2AADORA1
SCHEMBL2093666 0.66 CYP1A1 (0.41) ALDH1A1SMN1; SMN2ADORA2AMAPTMAPK1
SCHEMBL5754678 0.66 HSP90AA1 (0.38) ALDH1A1SMN1; SMN2KDM4EADORA2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165332-A1 SULFONAMIDES AND SULFAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2012-06-28 — — US disclosed
EP-2443095-A1 SULFONAMIDES AND SULFAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2012-04-25 — — EP disclosed
WO-2010146132-A1 SULFONAMIDES AND SULFAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165332-A1 SULFONAMIDES AND SULFAMIDES AS ZAP-70 INHIBITORS ZAP70, LCK, SYK ALDH1A1 3211/4885SMN1; SMN2 2743/4885KDM4E 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback